Deucravacitinib shows ‘superior efficacy’ in psoriatic arthritis at 52 weeks

Deucravacitinib demonstrated “superior efficacy” and tolerability vs. placebo at 16 weeks, and sustained efficacy through 52 weeks, in adults with active psoriatic arthritis, according to data published in Arthritis & Rheumatology. Philip J. Mease, MD, of Swedish Medical Center and the University of Washington, in Seattle, and colleagues previously published results at 16